Lipid Therapeutics Successfully Files a U.S. IND for LT-02, a Novel Barrier Function Therapy for Ulcerative Colitis
4/10/2013 9:45:46 AM
More...
|
Lipid Therapeutics Licenses European Rights to its Lead Product, LT-02, to Co-development Partner Dr. Falk Pharma GmbH
3/8/2012 10:40:53 AM
More...
|
Lipid Therapeutics Announces Positive Topline Phase IIb Results With LT-02 in Patients With Ulcerative Colitis
6/22/2011 6:37:43 AM
More...
|
Lipid Therapeutics Announces Start of Phase IIb Clinical Trial
1/29/2010 11:31:58 AM
More...
|